- 共同开发针对实体肿瘤的下一代细胞疗法
萨默塞特，新泽西，美国； 东京，日本；5月4日
致力于开发创新细胞疗法的临床阶段的生物制药公司传奇生物今天欣然宣布与Noile-Immune 生物技术公司（Noile）的合作。双方达成达成了关于Noile公司的 PRIME 技术的授权和合作协议。PRIME技术运用细胞分泌白细胞介素7（Interlukin-7, IL7）和趋化因子配体19 （Chemokine C-C motif ligand 19, IL-19），从而增强T淋巴细胞的增殖和在体内的迁徙能力。根据此协议，传奇生物将使用Noile的PRIME技术来增强CAR-T和TCR-T，以及病人T细胞的扩增和向肿瘤趋化的能力。
“黄金城集团很高兴与Noile建立战略合作关系，把黄金城集团在细胞治疗领域的研发和Noile的PRIME技术相结合。”传奇生物的首席科学官范晓虎博士评论道，“黄金城集团致力于将传奇的针对实体瘤的细胞疗法和Noile的创新技术相结合，力争为癌症病人开发新型的高度有效的疗法。”
“细胞治疗正往实体瘤领域拓展，关于增强CAR-T往肿瘤部位迁徙的能力对于产品开发非常重要。”传奇生物董事会董事，首席执行官许远博士评论道，“这次合作显示了传奇生物致力于为实体肿瘤开发创新疗法的决心。”
“与传奇生物达成战略合作是一项重要成就。传奇生物已经将细胞疗法带入临床开发阶段，并显示了细胞治疗的希望和前景。”Nolie的董事，科学创始人 Koji Tamada博士说到，“从科学的角度，将PRIME技术和传奇生物的创新项目相结合，黄金城集团的目标是对多种实体瘤开发高效的疗法，进一步拓展肿瘤免疫治疗的应用。”
“这次与传奇生物达成的合作再次显示了业界对PRIME技术的热情”，Noile首席执行官Hidenobu Ishizaki 评论道，“这次合作将加快创新细胞免疫治疗的开发。黄金城集团十分期待和传奇生物的合作，共同把癌症治疗的革新技术带给病患。”
在这项合作中，传奇生物和Noile 将共同开发不多于2个癌症靶点项目。传奇将获得PRIME技术在CAR-T和TCR-T开发中的使用权。 对每个合作的项目，传奇将支付总计可达七千万美金的费用，涵盖开发，申报和商业化等里程碑。Noile 也享有商品化以后个位数百分比的销售分成的权益。
关于传奇生物
传奇生物是一家在临床阶段的全球生物制药公司，致力于针对癌症和其它适应症的创新细胞疗法的开发。传奇生物公司已在美国，欧洲，和中国均有运营。更多讯息请访问//www.legendbiotech.com/。
关于Noile-Immune 生物技术公司
位于日本东京的Noile-Immune 生物技术公司致力于运用创新技术开发和商品化肿瘤免疫疗法。公司通过与包括山口大学和日本国家癌症中心的合作，开发新颖的肿瘤免疫疗法，为病患提供一流的治疗方案。更多信息，请访问//www.noileimmune.com/english/home/。
关于前瞻性陈述的注意事项
This information constitutes forward-looking statements relating to the business of Legend, including express or implied discussions regarding the anticipated benefits from the collaboration agreement with Noile-Immune and its PRIME technology and the ability to develop potential new therapies to address cancer in solid tumors, the clinical development of its product candidates and potential attributes and benefits of such product candidates. Such forwardlooking statements reflect the current views of Legend’s management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, Legend’s expectations could be affected by, among other things, uncertainties involved in the ability to implement PRIME technology into Legend’s product candidate pipeline, the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulationgenerally; Legend’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
The safety and efficacy of the product candidates and/or uses under investigation have not been established. There is no guarantee that the product candidates will receive health authority approval or become commercially available in any country for the uses being investigated.
The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.
传奇生物媒体和投资人联络
媒体联络
Deborah Wong, Executive Director, Strategic Marketing & Corporate
Communication, Legend Biotech
deborah.wong@legendbiotech.com or media@legendbiotech.com
投资者关系
Jessie Yeung, Head of Corporate Finance and Investor Relations,
Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com
Noile-Immune 联系方式
Tsutom Tokashiki, Executive Director, Senior Vice President,
Business Development, Noile-Immune Biotech
ir@noile-immune.com
